description 

Tada lafil cas:171596-29-5 99% White powder white powder 171596-29-5 

CAS no. : 171596-29-5
Molecular formula: C22H19N3O4
Molecular weight: 389.4
EINECS no. :
Related Categories: Active Pharmaceutical Ingredients; Raw materials of health care products; Cnbio; Erectile Dysfunction; Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals; API's;  and Hormone; Pharmaceutical raw materials; Active pharmaceutical ingredients. Inhibitor; Intermediates; API;  NUCYNTA; Standard; Reference substance; Chinese medicine reference substance; Other scientific research apis
property
The melting point of 298-300 ° C
Storage conditions Hygroscopic, -20? Warenarenc, Under Inert Atmosphere
171596-29-5 CAS DataBase Reference

Use and synthesis method of :
Treatment of male erectile dysfunction drugs is tada lafil, is by the lilly pharmaceutical companies to develop an oral medicines to treat male erectile dysfunction, belong to the second generation of phosphodiesterase 5 inhibitors, research report, compared , work very quickly, about 15 ~ 20 min work, lasting effect of 36 h. T1/2 to 17.5 h. In a study of 348 men with mild to severe erectile dysfunction, patients randomized to tada lafil 20mg or placebo showed improved sexal success at both 24 and 36 hours compared with placebo, with most men having two successful seual encounters at 36 hours. There was no difference in the incidence and severity of adverse drug reactions compared with placebo. Headache and indigestion occurred in more than 5% of the men in the Tada lafil group.
[Adverse reactions] No serious adverse reactions were observed, such as facial flushing and visual abnormalities. Occasionally headache, dyspepsia.
[Precautions] Patients who are taking nitrates, angina pectoris, heart disease, uncontrolled hypertension or hypotension, and patients who have had stroke in the past 6 months are prohibited.
Use Phosphodiesterase 5 inhibitor, for the treatment of male erectile dysfunction, the second generation phosphodiesterase 5 inhibitor, for the treatment of male BO dysfunction

1, Product title:

2, Product Description:

Tada lafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), And benign prostatic hypertrophy.8,9 It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.2

3, Product parameter table:

product description:

 developed and produced by Eli Lilly, is the only long-acting PDE-5 inhibitor approved by the US FDA and CFDA. Oral PDE-5 inhibitors for the treatment of male erectile dysfunction (ED) are recommended as first-line treatment for ED by medical guidelines in several countries and regions (e.g., THE United States, Europe, China, Japan, etc.).
products are available in two sizes in the Chinese market: 20mg (for as needed) and 5mg (once daily). once-daily is the only once-daily PDE-5 inhibitor approved by CFDA for the treatment of ED in China. It is effective on the second day at the earliest and reaches a stable blood concentration in 5 days. Cut the link between taking medication and having sex, and respond to sex initiated by your partner.
Clinical studies have shown that enhances the antihypertensive effect of nitrate drugs. Therefore, tablets are strictly prohibited for patients who are taking any form of nitrate medication